Noncellular Immune Therapies for Non-Hodgkin Lymphoma.
Hematol Oncol Clin North Am. 2019 Aug;33(4):707-725
Authors: Herrera AF
Abstract
Non-Hodgkin lymphomas (NHL) are a diverse group of diseases, encompassing mature B-cell, T-cell, and natural killer cell malignancies and ranging in behavior from indolent to highly aggressive. For many years, the traditional treatment of NHL centered on chemotherapy. However, the introduction of rituximab ushered in the era of immunotherapy for NHLs. This article reviews novel immune therapies that have been used for the treatment of NHL. The data supporting the use of rituximab have been reviewed extensively; this article focuses on novel immunotherapies other than rituximab that remain in use or are actively being studied in clinical trials.
PMID: 31229164 [PubMed - in process]